Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
14 employees
CiVi Biopharma: A US-based biotech firm specializing in R&D for cardiovascular and metabolic diseases.
HQ
Founded
2016
Founded with a mission to innovate in the biopharmaceutical sector, CiVi Biopharma is a clinical-stage biotechnology company based in the United States. The company focuses on research and development of novel oral antisense oligonucleotide therapies targeting cardiovascular and metabolic diseases. By leveraging cutting-edge science, CiVi Biopharma aims to address significant unmet medical needs in these critical areas.
CiVi Biopharma's leadership includes experienced professionals from the biotech and pharmaceutical industries, contributing to its strategic direction and scientific advancements. The company has garnered attention for its promising pipeline, including key projects like CiVi 030 and CiVi 008. Through its innovative approach and dedicated R&D efforts, CiVi Biopharma is making a substantial impact on the treatment landscape for cardiovascular and metabolic conditions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Biopharmaceuticals
Technology
Biotech
Tags
Healthtech
Model Types
Software, Research
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was CiVi Biopharma founded?
CiVi Biopharma was founded in 2016.
Where is CiVi Biopharma's headquarters located?
CiVi Biopharma's headquarters is located in West Conshohocken, PA, US.
When was CiVi Biopharma's last funding round?
CiVi Biopharma's most recent funding round was for $49M (USD) in May 2018.
How many employees does CiVi Biopharma have?
CiVi Biopharma has 14 employees as of Feb 4, 2024.
How much has CiVi Biopharma raised to-date?
As of July 05, 2023, CiVi Biopharma has raised a total of $89M (USD) since May 22, 2018.
Add Comparison
Total Raised to Date
$89M
USD
Last Update May 22, 2018
Last Deal Details
$49M
USD
May 22, 2018
Series Unknown
Current Employees
14
Last updated: Feb 4, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts